What Analysts Think of Eli Lilly Stock Ahead of Earnings

Core Insights - Eli Lilly (LLY) is anticipated to report fourth-quarter earnings, with expectations of increased sales and profits following the resolution of shortages for its weight-loss drugs [1][7] Financial Performance - Analysts project Eli Lilly will achieve $13.63 billion in revenue for the fourth quarter, representing a year-over-year increase of over 45% due to the success of its weight-loss drugs [3] - Net income is expected to more than double from the previous year to$ 4.58 billion, equating to $5.06 per share [3] Analyst Ratings - Among analysts tracking Eli Lilly, 10 out of 11 have rated the stock as a "buy," with one "hold" rating, and the average price target is nearly$ 986, indicating a 21% premium over recent trading levels [2] Sales Forecast Adjustments - The company had previously lowered its sales expectations for the fourth quarter, with anticipated revenue around $13.5 billion for the quarter and$ 45 billion for the full year [5][4] - CEO David Ricks indicated that production of salable doses of weight-loss drugs is expected to be 60% higher in the first half of this year compared to the same period in 2024 [5] Market Context - Eli Lilly and its competitor Novo Nordisk (NVO) have experienced demand consistently outpacing supply for their weight-loss drugs, with Lilly's products removed from the FDA's shortage list late last year [6] - Despite a recent decline from record levels, Eli Lilly shares have increased by over 20% in the past year [7]